Having trouble viewing this email? View it in your browser.
Musella Foundation Logo and Name of Email Blast
Wednesday, July 21, 2021
Issue 5832

The most important bill ever introduced into congress for brain tumor patients needs your support!
Click for details and to easily send letters.

Latest News

Discuss these articles in our forum!
  • KIYATEC Marks Glioblastoma Awareness Day by Initiating Use of 3D Predict™ Glioma Test Outside of Clinical Study         This is a new test that will be available starting today!  It can acurately predict which of several drugs would work best for your tumor, including Temodar.   The research has shown that in some Glioblastoma cases patients with unmethylated MGMT (whom we assume would not respond well to Temodar), this test predicted that it would work, and those patients did well. On the other hand, some patients with methylated MGMT (whom we think should do well with Temodar), this test said they would not respond and they did not.   It can also tell if Lomustine alone is a better choice than Temodar alone, and that the combination of Temodar and Lomustine is sometimes worse than one of them alone, and in other cases is the best choice. The test requires live tumor cells so you need to set it up a few days before your surgery so the surgeon can request a test kit. (Or if he already has the test kits, you just need to request the test).  I do not know the cost and if it is covered yet, so ask your doctor to check for you. I will have a webinar about this test on August 22nd. More details as it gets closer.     If you do the test, please tell us about your expeirence.

Sponsored By
Plus Therapeutics
Please Click On The Above Banner For More Details

To view past stories go to : https://virtualtrials.org/newsblast.cfm
To submit a story/press release go to: click here To unsubscribe, click here.
The article commentaries are the opinions of Al Musella, DPM and do not represent the official position of the Musella Foundation. Copyright 1992-2021 Musella Foundation - All rights reserved. No part of the Brain Tumor News Blast can be reproduced without the express written permission of the Musella Foundation.